Prostatype Genomics AB (publ)

DB:PGO0 Stock Report

Market Cap: €926.5k

Prostatype Genomics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Fredrik Rickman

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8yrs
CEO ownership0.02%
Management average tenure2.1yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO

Fredrik Rickman

8yrs

Tenure

Mr. Fredrik Rickman (Previously Fredrik Rickman) has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science...

Leadership Team

NamePositionTenureCompensationOwnership
Fredrik Rickman
CEO & MD8yrsno data0.018%
€ 163.6
Anders Koch
Chief Financial Officer1.3yrsno datano data
George Skinner
Vice President Commercial operationsno datano datano data
Emelie Berglund
Chief Technology Officer2.2yrsno data0.0011%
€ 10.3
Nicklas Rosendal
Communications Director3.3yrsno datano data
Joakim Soderin
Chief Auditor2.6yrsno datano data
Gerald Andriole
Global Chief Medical Officer1.7yrsno datano data
Steven Gaal
President US operations2yrsno datano data
Katarina Sjöberg
QA & RA Manager2yrsno datano data
Mats Bergström
Sales Director of EMEAno datano datano data

2.1yrs

Average Tenure

Experienced Management: PGO0's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anders Lundberg
Independent Chairman of the Board8yrsno datano data
Mattias Prage
Independent Director2.6yrsno datano data
Hakan Englund
Independent Director6yrsno data0.85%
€ 7.9k
Michael Haggman
Independent Director7yrsno data7.49%
€ 69.4k
Rolf Skoglund
Member of Advisory Boardno datano datano data
Jörgen Dahlström
Independent Director1.2yrsno data0.010%
€ 93.5
Johan Waldhe
Directorless than a yearno datano data

4.3yrs

Average Tenure

Experienced Board: PGO0's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:26
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prostatype Genomics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Johan UnnerusRedeye